FOXO4-DRI vs SHLP-6
FOXO4-DRI has senescent-cell and mouse-model studies. A SHLP-6 experiment found increased apoptosis in two cell lines but did not test senescent-cell clearance. Human longevity benefits are unestablished for both.
Last updated: September 28, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
FOXO4-DRI
Dossier overview
SHLP-6
Dossier overview
What was studied
| Question | FOXO4-DRI | SHLP-6 |
|---|---|---|
| Experimental focus | FOXO4-p53 signaling and apoptosis in senescent-cell models | Mitochondria-derived peptide tested for effects on cell viability and apoptosis |
| Direct finding cited here | Senescent-cell and selected mouse outcomes | Increased apoptosis in mouse NIT-1 beta cells and human 22Rv1 prostate-cancer cells in culture |
| Selective senescent-cell clearance in people | Not established | Not established; the cited SHLP-6 experiment did not use a senescence-clearance model |
| Human longevity or safety outcome | Not established | Not established |
The original FOXO4-DRI study reported apoptosis in experimental senescent-cell systems and changes in selected measures in naturally aged and accelerated-aging mice. It was published in Cell in 2017. These model results do not establish human healthspan improvement or universal selectivity. Baar et al., 2017
SHLP-6 was described with the small humanin-like peptide family in a 2016 Aging paper. In that paper, SHLP-6 increased an apoptosis readout in NIT-1 and 22Rv1 cultured cells. The study’s deeper metabolic and animal experiments focused on SHLP-2 and SHLP-3; their findings cannot be assigned to SHLP-6. The 22Rv1 cells were human-derived, but no person received SHLP-6 in that experiment. A pro-apoptotic cell-line result alone does not establish senolytic action, cancer treatment or longevity benefit. Cobb et al., 2016
How to interpret the difference
The cited papers do not directly compare FOXO4-DRI with SHLP-6 or test a combination. They do not establish that the compounds are compatible or synergistic. Model context also matters for FOXO4-DRI: a pulmonary-hypertension mouse study reported worse pulmonary measures after senescent-cell removal, including a FOXO4-DRI comparison in one mouse model. This does not quantify a human risk. Born et al., 2023
Evidence for human longevity outcomes is very low for each peptide. This comparison describes research and is not medical advice or guidance for self-treatment.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.